title: Cellular therapy for haematological malignancies.
abstract: The aim of this review was to summarize the recent progress made in the field of cellular therapeutics in haematological malignancy. The review also examined the role that the National Transfusion Services might play in the manufacture of new cellular therapeutic agents, given both their expertise in the safe provision of blood products and their possession of accredited cell manipulation facilities. Cellular therapy is entering an era in which novel cellular products will find increasing clinical use, particularly in the areas of haematopoietic stem cell transplantation and immunotherapy. The production of novel cell-based therapies, both in Europe and North America, is now under strict regulatory control and therefore collaboration with the National Transfusion Services in the manufacture of these agents may well be beneficial if the production standards demanded by the regulatory authorities are to be fulfilled.
authors.affiliation: SNBTS Cell Therapeutics Group, University of Edinburgh-Leukaemia Research Fund, John Hughes Bennett Laboratory, Edinburgh, UK. huw.roddie@luht.scot.nhs.uk
authors.forename: P H
authors.initials: PH
authors.lastname: Roddie
authors.forename: M L
authors.initials: ML
authors.lastname: Turner
mesh_terms: D033161:Government Regulation; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D014181:Transplantation Immunology; D016896:Treatment Outcome